Table 4.
Difference between active and inactive segment in training set
| Parameters | None-active (n = 64) | Active (n = 77) | p value |
|---|---|---|---|
| Age (years) | 28.000 [23.000, 33.000] | 29.000 [23.000, 37.000] | 0.382 |
| Sex (F/M) | 27/37 | 34/43 | 0.814 |
| Wall thickening (mm) | 3.000 [2.000, 5.000] | 7.000 [5.000, 8.000] | < 0.001 |
| Segmental mural hyperenhancement (Stratified/Homogeneous) | 6/58 | 21/56 | 0.007 |
| Stricture (Yes/No) | 3/61 | 29/48 | < 0.001 |
| with upstream dilation (Yes/No) | 0/64 | 8/69 | nan |
| Fibrofatty proliferation | 10/54 | 28/49 | 0.006 |
| Engorged vasa recta (Yes/No) | 0/64 | 30/47 | nan |
| Inflammation (Yes/No) | 3/61 | 19/58 | 0.001 |
| Regional Lymph node (diameter ≥ 0.5 cm) (Yes/No) | 14/50 | 43/34 | < 0.001 |
| Arterial Phase | |||
| Zeff | 7.900 [7.700, 8.160] | 8.360 [8.160, 8.535] | < 0.001 |
| IC (mg/mL) | 1.030 [0.680, 1.500] | 2.010 [1.550, 2.350] | < 0.001 |
| NIC | 0.095 [0.065, 0.129] | 0.160 [0.120, 0.188] | < 0.001 |
| λ HU | 1.272 [0.910, 1.775] | 2.433 [1.745, 2.923] | < 0.001 |
| Venous Phase | |||
| Zeff | 8.076 ± 0.237 | 8.305 ± 0.191 | < 0.001 |
| IC (mg/mL) | 1.377 ± 0.481 | 1.851 ± 0.427 | < 0.001 |
| NIC | 0.318 ± 0.098 | 0.405 ± 0.096 | < 0.001 |
| λ HU | 1.691 ± 0.603 | 2.322 ± 0.515 | < 0.001 |
Zeff Z-effective, IC iodine concentration, NIC normalised iodine concentration, λ HU slope of the energy spectrum curve